Astellas partners with biotech startup for safer gene therapy treatment of neuromuscular condition.

Astellas is partnering with startup Kate Therapeutics to revisit X-linked myotubular myopathy, a fatal neuromuscular condition for which there are currently no treatments. The move comes four years after Audentes Therapeutics presented powerful data on a young boy with the condition at a cell and gene therapy conference.